Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equ… Read more
Harvard Bioscience Inc (HBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.059x
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of 0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($830.00K) by net assets ($14.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harvard Bioscience Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PetVivo Holdings Inc
NASDAQ:PETV
|
-0.438x |
|
PLAYMATES HLDGS NEW HD-10
F:PLJ2
|
N/A |
|
Tirathai Public Company Limited
BK:TRT
|
0.287x |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
-0.008x |
|
ZUE SA
WAR:ZUE
|
0.137x |
|
Carma Limited
AU:CMA
|
N/A |
|
Grand-Tek Technology Co. Ltd.
TWO:3684
|
0.060x |
|
Peak Resources Limited
PINK:PKREF
|
0.000x |
Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $63.34 Million | $1.44 Million | 0.023x | -88.16% |
| 2023-12-31 | $73.07 Million | $14.03 Million | 0.192x | +1103.48% |
| 2022-12-31 | $72.22 Million | $1.15 Million | 0.016x | +5.42% |
| 2021-12-31 | $83.40 Million | $1.26 Million | 0.015x | -87.56% |
| 2020-12-31 | $76.68 Million | $9.33 Million | 0.122x | +23.54% |
| 2019-12-31 | $81.69 Million | $8.05 Million | 0.099x | +245.36% |
| 2018-12-31 | $82.18 Million | $2.34 Million | 0.029x | +118.30% |
| 2017-12-31 | $80.90 Million | $1.06 Million | 0.013x | -82.48% |
| 2016-12-31 | $72.20 Million | $5.38 Million | 0.075x | +720.68% |
| 2015-12-31 | $77.60 Million | $705.00K | 0.009x | -80.07% |
| 2014-12-31 | $95.47 Million | $4.35 Million | 0.046x | +6.06% |
| 2013-12-31 | $94.48 Million | $4.06 Million | 0.043x | -44.46% |
| 2012-12-31 | $104.21 Million | $8.06 Million | 0.077x | +16.38% |
| 2011-12-31 | $95.50 Million | $6.35 Million | 0.066x | -51.20% |
| 2010-12-31 | $90.25 Million | $12.29 Million | 0.136x | -37.91% |
| 2009-12-31 | $75.26 Million | $16.51 Million | 0.219x | +59.05% |
| 2008-12-31 | $66.72 Million | $9.20 Million | 0.138x | -15.18% |
| 2007-12-31 | $74.14 Million | $12.05 Million | 0.163x | +39.88% |
| 2006-12-31 | $71.88 Million | $8.36 Million | 0.116x | +53.09% |
| 2005-12-31 | $68.42 Million | $5.20 Million | 0.076x | -30.72% |
| 2004-12-31 | $104.36 Million | $11.44 Million | 0.110x | +434.44% |
| 2003-12-31 | $98.88 Million | $2.03 Million | 0.021x | +126.72% |
| 2002-12-31 | $88.38 Million | $799.46K | 0.009x | -85.24% |
| 2001-12-31 | $66.81 Million | $4.10 Million | 0.061x | +49.49% |
| 2000-12-31 | $52.33 Million | $2.15 Million | 0.041x | -88.81% |
| 1999-12-31 | $7.98 Million | $2.93 Million | 0.367x | -- |